Vireo Growth Inc.
VREOF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VREOF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$773.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Run Vireo Growth Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vireo Growth Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 2.16
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$4
| Holder | Shares | Value |
|---|---|---|
| resources management corp /ct/ /adv | 10,000 | $4 |
Governance
Frequently asked questions
Who is the CEO of Vireo Growth Inc.?
Mr. John Michael Mazarakis is the chief executive officer of Vireo Growth Inc. (VREOF).
Where is Vireo Growth Inc. headquartered?
Vireo Growth Inc. (VREOF) is headquartered in Minneapolis, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.